Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase 3A (PDE3A) is an enzyme that hydrolyzes cAMP and cGMP, thereby regulating their intracellular concentrations and modulating various signaling pathways. It plays a critical role in cardiovascular tissues, cancer biology, and gastrointestinal physiology. Mutations in PDE3A are linked to hypertension with brachydactyly syndrome, while overexpression is implicated in breast cancer progression. Selective inhibitors like cilostazol are used as antiplatelet agents and show promise in cancer therapy.
Selective inhibition of PDE3A, leading to increased intracellular cAMP and cGMP levels in target cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase 3A (PDE3A).